Aligos Doses First Patient in Phase 1 Trial of Next-Gen HBV Drug ALG-170675
ALGS sits 76% above its 52-week low of $3.98.
Summary
Aligos has dosed the first participant in the Phase 1 study of ALG-170675, its next-generation antisense oligonucleotide for chronic hepatitis B, run by partner Amoytop in China. The study will evaluate safety, tolerability, PK, and PD in healthy volunteers and later in HBV patients, with the HBV cohort expected to start in Q4 2026. This is a new clinical milestone for a second HBV asset, following the recent $25M upfront payment and Phase 2 enrollment for pevifoscorvir sodium. The company's cash runway only extends into Q4 2026, so advancing this partnered program adds pipeline value without immediate internal cost. Watch for initial safety data from the SAD portion and the start of the HBV cohort later this year.
At the time of this announcement, ALGS was trading at $7.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $43.7M. The 52-week trading range was $3.98 to $13.69. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.